Jobevne Injection
Product Images NDC 83257-009

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Jobevne (NDC 83257-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Biologics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jobevne Injection 100 mg/4 mL Carton Label (Image 10)

Label for JOBEVNE (bevacizumab-nwgd) Injection, 100 mg per 4 mL (25 mg/mL), a single-dose vial for intravenous infusion after dilution. The label includes the Biocon Biologics Inc. logo and states no preservative is present. It features dosage and storage instructions, a barcode, and manufacturer information indicating the product is made in India and distributed by Biocon Biologics Inc.*

FDA Label Image

Jobevne Injection 400 mg/16 mL Carton Label (Image 11)

Jobevne 400 mg / 16 mL (25 mg/mL) injection box label for bevacizumab-nwgd, a human prescription drug by Biocon Biologics Inc. The label states the product is for intravenous infusion after dilution with no preservative. It indicates a single-dose vial and includes storage and manufacturing information. The NDC number 83257-010-11 appears on the label.*

FDA Label Image

Figure 1: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study Avf2107g (Image 01)

A survival curve chart comparing the proportion surviving over a 30-month duration between two groups: IFL plus Placebo and IFL plus Bevacizumab. The x-axis represents duration of survival in months, and the y-axis shows the proportion surviving. The chart includes the number of patients at risk at multiple time points for each group.*

FDA Label Image

Figure 2: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study mL18147 (Image 02)

A survival curve chart showing the proportion of patients surviving over a 48-month study period comparing two treatments: chemotherapy alone and chemotherapy plus bevacizumab. The x-axis represents study months, and the y-axis shows the proportion surviving. A table below the graph lists patient numbers at risk at various time points for both groups.*

FDA Label Image

Figure 3: Kaplan-meier Curves For Duration Of Survival In First-line Non-squamous Non-small Cell Lung Cancer In Study E4599 (Image 03)

A survival curve chart depicting the proportion of patients surviving over time in months, comparing two groups: PC alone (n=444) and PC plus Bevacizumab (n=434). The x-axis represents duration of survival in months up to 50, and the y-axis shows proportion surviving from 0 to 1. The number of patients at risk at various time points is displayed below the graph for each group.*

FDA Label Image

Figure 4: Kaplan-meier Curves For Progression-free Survival In Metastatic Renal Cell Carcinoma In Study Bo17705 (Image 04)

A Kaplan-Meier curve showing progression-free survival over 24 months comparing Placebo + IFN-alfa versus Bevacizumab + IFN-alfa. The y-axis represents the proportion progression-free, and the x-axis shows time in months. The chart includes a table below indicating the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 5: Kaplan-meier Curves For Overall Survival In Persistent, Recurrent, Or Metastatic Cervical Cancer In Study Gog-0240 (Image 05)

A Kaplan-Meier survival curve chart depicting overall survival proportion over time in months for two groups: chemotherapy alone (n=225) and chemotherapy plus bevacizumab (n=227). The graph includes error bars and a table of numbers at risk for both groups at various time points up to 42 months.*

FDA Label Image

Figure 6: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Stage Iii Or Iv Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Following Initial Surgical Resection In Study Gog-0218 (Image 06)

A Kaplan-Meier survival curve chart depicting progression-free survival over months. The y-axis shows the proportion progression-free, ranging from 0 to 1, while the x-axis represents progression-free survival in months up to 48. Three patient groups (CPB, CPB15, CPB15b) are compared with distinct survival curves and respective numbers of patients at risk listed below the x-axis.*

FDA Label Image

Figure 7: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Mo22224 (Image 07)

A Kaplan-Meier curve chart depicting progression-free survival over time in months. The graph compares two groups: CT (chemotherapy) with 182 participants and CT + BV (chemotherapy plus bevacizumab) with 179 participants. The vertical axis shows the proportion of progression-free patients, while the horizontal axis represents duration in months, with survival decreasing over time in both groups.*

FDA Label Image

Figure 8: Kaplan Meier Curves For Progression-free Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Avf4095g (Image 08)

A Kaplan-Meier survival curve chart depicting progression-free survival over time (in months) for two treatment groups: CG+PI and CG+Bv. The chart shows the proportion of progression-free patients on the y-axis and time since randomization in months on the x-axis, with accompanying tabular data of sample sizes at various time points.*

FDA Label Image

Figure 9: Kaplan Meier Curves For Overall Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Gog-0213 (Image 09)

A survival curve chart comparing two randomized treatment groups over a study period measured in months. The chart displays the proportion of subjects surviving on the vertical axis and time in study months on the horizontal axis. Two lines represent different treatment arms, with a legend indicating their respective groups. The number of subjects at risk at various time points is shown below the horizontal axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.